AlmirallShare: new call looking for novel targets and concepts

11 October 2018

Spain largest drugmaker Almirall (ALM: MC) has launched AlmirallShare, a new call with the aim of finding novel targets and concepts in the treatment of dermatological diseases.

Targets of interest may be proteins or nucleic acids whose function can be modulated by a small molecule or biological therapy that have a scientific rationale in a dermatological disease. Concepts may be mechanisms, pathways, or cell players not previously linked to a disease of interest.

The call is open from October 10, 2018, until February 28, 2019, and is addressed to universities, research centers, start-ups, biotechs and pharma companies all over the world with an interest in pharmaceutical R&D.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK